Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

NCT01562444 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01562444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01562444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
March 8, 2012
Completion date
September 30, 2016
Enrollment
206 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tick borne encephalitis, virus diseases